Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Recurrent Ta Low-grade Non-muscle-invasive Bladder Cancer: What Are the Options?
Sorbonne Univ, ONCOTYPE URO, Hop Pitie Salpetriere, Paris, France.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Urology.ORCID iD: 0000-0001-8572-9957
Univ British Columbia, Urol Sci, Vancouver, BC, Canada.
2019 (English)In: EUROPEAN UROLOGY ONCOLOGY, ISSN 2588-9311, Vol. 2, no 6, p. 723-729Article in journal (Refereed) Published
Abstract [en]

Recurrent low-grade Ta tumours, classified as intermediate-risk non-muscle-invasive bladder cancer (NMIBC), have a high risk of recurrence but a low risk of progression. This case presents a 60-yr-old female with intermediate-risk NMIBC who has been treated with sequential courses of mitomycin C followed by bacillus Calmette-Guerin (BCG). She continued to develop multiple episodes of recurrence. The discussion addresses whether the best course is repeat transurethral resection of the bladder with continued monitoring, more of the same intravesical treatments, new methods of applying these treatments, or novel treatments that might involve enrolling the patient in a clinical trial. The biggest unmet need in the field comes from the lack of a molecular marker that could help select patients for aggressive strategies. Patient summary: Following treatment of intermediate-risk non-muscle-invasive bladder cancer with a fairly standard course of intravesical drug therapy, the patient, a relatively young woman, continued to develop recurrences of the bladder cancer. The authors discuss whether the best next course is "more of the same", device-assisted application of these treatments, or perhaps one of the new, still investigatory treatment approaches. Radical surgery (removal of the bladder) should not be necessary unless the recurrences show signs of disease progression. .

Place, publisher, year, edition, pages
ELSEVIER , 2019. Vol. 2, no 6, p. 723-729
Keywords [en]
Surveillance, Mutation, Immune checkpoint blockade, Urothelial cancer, Bladder, Neoplasm, Progression, Recurrence
National Category
Urology and Nephrology
Identifiers
URN: urn:nbn:se:uu:diva-398023DOI: 10.1016/j.euo.2019.06.003ISI: 000496493400015PubMedID: 31239237OAI: oai:DiVA.org:uu-398023DiVA, id: diva2:1375434
Available from: 2019-12-05 Created: 2019-12-05 Last updated: 2019-12-05Bibliographically approved

Open Access in DiVA

fulltext(868 kB)17 downloads
File information
File name FULLTEXT01.pdfFile size 868 kBChecksum SHA-512
6f822011caf65c38262fe843a1ce94c97d7a8cdd89a4f19ca00df890e4957538cbcadcd482f5dde672059fa94c0331cbe41918f5e46392d46f4ab0458886d639
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Malmström, Per-Uno
By organisation
Urology
Urology and Nephrology

Search outside of DiVA

GoogleGoogle Scholar
Total: 17 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 13 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf